Multidrug resistance in hepatocellular carcinoma

  • Baojun Duan
  • , Chen Huang
  • , Jun Bai
  • , Yu Lian Zhang
  • , Xi Wang
  • , Juan Yang
  • , Jun Li

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

26 Scopus citations

Abstract

Although there has been tremendous progress in the treatment of hepatocellular carcinoma over the past decades, multidrug resistance to chemotherapy and targeted therapy remains a major hindrance in its successful management. Multidrug resistance, whether intrinsic or extrinsic, is a multifactorial process that includes enhanced drug efflux, decreased drug uptake, intracellular sequestration, metabolic alterations, aberrant apoptotic and autophagic signaling, changes in tumor microenvironment, and acquisition of stem cell-like properties by the cancer cells. Although many experimental strategies have been developed to overcome drug resistance, translation of the knowledge to the clinic has not been crowned with success. This chapter provides an overview of the role of multidrug resistance in hepatocellular carcinoma and the potential approaches to overcome this obstacle.

Original languageEnglish
Title of host publicationHepatocellular Carcinoma
PublisherExon Publications
Pages141-158
Number of pages18
ISBN (Print)9780994438188
DOIs
StatePublished - 9 Oct 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ATP-binding cassette transporter
  • Drug efflux
  • Drug sequestration
  • Multidrug resistance
  • RNAi therapy

Fingerprint

Dive into the research topics of 'Multidrug resistance in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this